Pilot Study for the Development of a Diagnostic Score to Differentiate Myeloproliferative Neoplasms.

University Hospital, Angers133 enrolled

Overview

Prospective study for the development of a non-invasive score for differentiating prefibrotic myelofibrosis from essential thrombocytosis and overt myelofibrosis.

The diagnostic criteria for myeloproliferative neoplasia have recently been revised in the WHO 2016 classification, which now recognizes a new entity between essential thrombocythemia (TE) and overt myelofibrosis (or primary myelofibrosis): prefibrotic myelofibrosis. Prefibrotic myelofibrosis patients seem to have a poorer prognosis compared to essential thrombocythemia in term of overall survival and myelofibrotic evolution. The dichotomy between these diseases is based on the bone marrow biopsy evaluation and is challenging with a lack of reproducibility showed in the literature. This study aims to develop a diagnostic non-invasive score for differentiating prefibrotic myelofibrosis from essential thrombocytosis and overt myelofibrosis. The parameters studied are : * spleen fibrosis by elastography * plasma cytokines levels * mutationnal landscape by NGS * CD34 circulating cells Bone marrow biopsy were reviewed by 2 anatomopathologists. Number of patients to be enrolled : 130

Study Type

INTERVENTIONAL

Allocation

Purpose

DIAGNOSTIC

Masking

NONE

Enrollment

133

Conditions

Myeloproliferative Disorder Essential Thrombocythemia Primary Myelofibrosis, Prefibrotic Stage Primary Myelofibrosis, Fibrotic Stage

Interventions

Non-invasive diagnosis scoreDIAGNOSTIC_TEST

* spleen fibrosis by elastography * plasma cytokines levels * mutationnal landscape by NGS * CD34 circulating cells

Eligibility

Sex: ALLMin age: 18 YearsMax age: 99 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Adult (18 years of age or older) with the diagnosis of essential thrombocytosis, prefibrotic myelofibrosis or overt myelofibrosis according to WHO 2016 criteria; * Patient who has not received specific treatment for neoplasms; * Patient who has signed the consent to participate in the study; * Patient who has consented to be included in the "Malignant Haemopathies" collection at the University Hospital of Angers or Brest and for whom the samples necessary for the study are available in the biocollection. Exclusion Criteria: * Patient with another hematologic neoplasm or progressive cancer at the time of diagnosis; * Patient with a diagnosis of secondary myelofibrosis; * Pregnant or breastfeeding woman; * Person prived of liberty by judicial or administrative decision; * Person subject to a legal protection measure;

Locations (2)

Chu Angers

Angers, France

CHRU de Brest - Hôpital Morvan

Brest, France

Outcomes

Primary Outcomes

WHO 2016 criteria for prefibrotic myelofibrosis, essential thrombocytosis and overt myelofibrosis diagnosis

Assessment of the non-invasive diagnostic score against the WHO diagnosis

Time frame: At the time of diagnosis : disease classification

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.